Related Experiment Videos
Colchicine induced rhabdomyolysis
I Chattopadhyay1, H G Shetty, P A Routledge
1Department of Geriatric Medicine, Ysbyty Gwynedd Hospital, Bangor, UK.
Postgraduate Medical Journal
|February 27, 2001
Summary
A rare case of colchicine-induced rhabdomyolysis occurred in a 73-year-old man. Discontinuing colchicine resolved the muscle breakdown, highlighting a rare adverse effect of this gout medication.
Area of Science:
- Pharmacology
- Toxicology
- Nephrology
Background:
- Colchicine is a common medication for gout and other inflammatory conditions.
- Neuromuscular adverse effects of colchicine are known but typically involve myopathy.
- Rhabdomyolysis, a severe form of muscle breakdown, is a rare complication of colchicine therapy.
Observation:
- A 73-year-old male patient with multiple comorbidities presented with diffuse muscle pain.
- The patient had been on an increased dose of colchicine (1.5 mg daily) for gout exacerbation for six weeks.
- Clinical presentation and laboratory investigations confirmed rhabdomyolysis.
Findings:
- Discontinuation of colchicine led to the resolution of clinical symptoms and biochemical markers of rhabdomyolysis.
- This case represents the fourth documented instance of colchicine-induced rhabdomyolysis in medical literature.
- The patient's pre-existing conditions may have contributed to the susceptibility to colchicine toxicity.
Implications:
- Clinicians should be aware of the potential for rare but severe adverse effects like rhabdomyolysis with colchicine use, especially at higher doses or in susceptible patients.
- Early recognition and discontinuation of the offending agent are crucial for managing colchicine-induced rhabdomyolysis.
- Further research may be needed to identify risk factors and mechanisms underlying colchicine-induced rhabdomyolysis.